The FDA's Abbreviated New Drug Application (ANDA) process allows generic drugs to gain approval by proving equivalence to brand names, skipping costly clinical trials. This guide explains the Hatch-Waxman Act, bioequivalence requirements, and how ANDAs drive down healthcare costs.